Compare
Pulmatrix, Inc. vs Lexaria Bioscience Corp. vs Cadrenal Therapeutics, Inc. vs Protagenic Therapeutics, Inc.new
| Latest fiscal year | Pulmatrix, Inc. PULM | Lexaria Bioscience Corp. LEXX | Cadrenal Therapeutics, Inc. CVKD | Protagenic Therapeutics, Inc.new PTIXRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2026-03-31 |
| Revenue | n/a | $705.9K | n/a | n/a |
| Revenue growth (YoY) | n/a | +52.0% | n/a | n/a |
| Gross margin | n/a | 99.6% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$5.16M | -$11.90M | -$13.24M | $1.37M |
| EPS (Diluted) | -$1.41 | -$0.66 | -$6.64 | $0.59 |
| Operating cash flow | -$5.43M | -$10.45M | -$12.60M | -$2.81M |
| Free cash flow | n/a | -$10.48M | -$12.61M | -$2.81M |
| Cash & equivalents | $4.09M | n/a | $4.01M | n/a |
| Total assets | $4.14M | $4.18M | $4.33M | $3.65M |
| Total liabilities | $329.0K | $1.57M | $1.59M | $1.03M |
| Shareholders' equity | $3.81M | $2.99M | $2.74M | $2.62M |
| Return on year-end equity | -135.5% | -398.1% | -483.3% | 52.2% |
| Shares outstanding | 3.65M | 19.56M | 2.34M | 1.81M |
Revenue, most recent five fiscal years
| Fiscal year | Pulmatrix, Inc. | Lexaria Bioscience Corp. | Cadrenal Therapeutics, Inc. | Protagenic Therapeutics, Inc.new |
|---|---|---|---|---|
| Latest | $7.81M Ended 2024-12-31 | $705.9K Ended 2025-08-31 | n/a | n/a |
| 1 year earlier | $7.30M Ended 2023-12-31 | $464.3K Ended 2024-08-31 | n/a | n/a |
| 2 years earlier | $6.07M Ended 2022-12-31 | $226.2K Ended 2023-08-31 | n/a | n/a |
| 3 years earlier | $5.17M Ended 2021-12-31 | $255.4K Ended 2022-08-31 | n/a | n/a |
| 4 years earlier | $12.63M Ended 2020-12-31 | $722.7K Ended 2021-08-31 | n/a | n/a |